• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Should Opioid Medications Be Left Out of the Treatment Plan?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE: 

  • Krebs et al. (JAMA, 2018) assessed whether there was a difference in long-term outcomes of opioids compared with nonopioid medications for chronic back, knee or hip pain 

METHODS: 

  • Pragmatic, 12-month, randomized trial with masked outcome assessment 
  • Patients had moderate to severe chronic back pain or hip or knee osteoarthritis pain despite analgesic use 
  • Patients were recruited from Veterans Affairs primary care clinics, with a 1- to 3-year follow-up 
  • Opioid and nonopioid medication therapy followed a treat-to-target strategy aiming for improved pain and function 
  • The groups were started on the following medications
    • Opiod Group: immediate-release morphine, oxycodone, or hydrocodone/acetaminophen 
    • Nonopiod group: acetaminophen (paracetamol) or nonsteroidal anti-inflammatory drugs 
  • The primary outcome was pain-related function over 12 months, measured using the Brief Pain Inventory [BPI] interference scale 
  • The primary adverse outcome was medication-related symptoms (patient-reported checklist; range, 0-19) 
  • Secondary outcome was pain intensity (BPI severity scale) 
  • For both BPI scales (range, 0-10; higher scores = worse function or pain intensity), a 1-point improvement was clinically important 

RESULTS: 

  • 240 patients were randomized and completed the trial 
    • Mean age, 58.3 years; women made up 13% of participants
  • Pain related function did not differ between groups (p = .58) 
    • Mean 12-month BPI interference was 3.4 for the opioid group and 3.3 for the nonopioid group (difference, 0.1 [95% CI, −0.5 to 0.7]) 
  • Pain intensity was significantly better in the nonopioid group over 12 months (p= .03) 
    • Mean 12-month BPI severity was 4.0 for the opioid group and 3.5 for the nonopioid group (difference, 0.5 [95% CI, 0.0 to 1.0]) 
  • The opioid group had significantly greater adverse medication-related symptoms over 12 months (p = .03) 
    • Mean medication-related symptoms at 12 months were 1.8 in the opioid group and 0.9 in the nonopioid group (difference, 0.9 [95% CI, 0.3 to 1.5]) 

CONCLUSION: 

  • Opioid medications did not significantly improve pain-related function and may lead to greater adverse symptoms, compared to nonopioid treatment 

Learn More – Primary Sources: 

Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis PainThe SPACE Randomized Clinical Trial

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Do Non-Opioids Work as Well as Opioids for Acute Extremity Pain? 
Fixed-Interval or On-Demand Treatment Better for C-Section Pain?
Can Self-Acupressure Apps Relieve Dysmenorrhea?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site